MIRO Stock Overview
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Miromatrix Medical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.39 |
| 52 Week High | US$3.73 |
| 52 Week Low | US$0.91 |
| Beta | 0.015 |
| 11 Month Change | 1.50% |
| 3 Month Change | 149.26% |
| 1 Year Change | 18.53% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.76% |
Recent News & Updates
Recent updates
Miromatrix Medical (NASDAQ:MIRO) Will Have To Spend Its Cash Wisely
Oct 28
We're A Little Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Rate
Jul 01Here's Why We're A Bit Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation
Mar 08Here's Why We're Watching Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation
Sep 30Miromatrix gets US patent for recellularizing technology for use in organ transplant
Aug 25Miromatrix Medical GAAP EPS of -$0.40 misses by $0.07, revenue of $3.95M
Aug 15Shareholder Returns
| MIRO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 1.2% | -7.2% | -1.2% |
| 1Y | 18.5% | 1.2% | 30.4% |
Return vs Industry: MIRO exceeded the US Life Sciences industry which returned -8.9% over the past year.
Return vs Market: MIRO exceeded the US Market which returned 17.1% over the past year.
Price Volatility
| MIRO volatility | |
|---|---|
| MIRO Average Weekly Movement | 61.8% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MIRO's share price has been volatile over the past 3 months.
Volatility Over Time: MIRO's weekly volatility has increased from 33% to 62% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 76 | Jeff Ross | www.miromatrix.com |
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company’s proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute.
Miromatrix Medical Inc. Fundamentals Summary
| MIRO fundamental statistics | |
|---|---|
| Market cap | US$92.95m |
| Earnings (TTM) | -US$27.41m |
| Revenue (TTM) | US$958.03k |
97.0x
P/S Ratio-3.4x
P/E RatioIs MIRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MIRO income statement (TTM) | |
|---|---|
| Revenue | US$958.03k |
| Cost of Revenue | US$500.00k |
| Gross Profit | US$458.03k |
| Other Expenses | US$27.87m |
| Earnings | -US$27.41m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.00 |
| Gross Margin | 47.81% |
| Net Profit Margin | -2,861.11% |
| Debt/Equity Ratio | 2.5% |
How did MIRO perform over the long term?
See historical performance and comparison